Dexcom held its 2026 Annual Meeting of Stockholders on 5 27, 2026, the company said. As of the record date on April 1, 2026, 336,525,352 of 385,872,977 outstanding shares of common stock were present in person or represented by proxy, constituting a quorum for the transaction of business.

1. 01

   Dexcom held its 2026 Annual Meeting of Stockholders on 5 27, 2026, the company said. As of the record date on April 1, 2026, 336,525,352 of 385,872,977 outstanding shares of common stock were present in person or represented by proxy, constituting a quorum for the transaction of business.

2. 02

   All 12 director nominees were elected to serve until Dexcom's 2027 annual meeting of stockholders or until their earlier death, resignation or removal, the company said. Steven Altman received 299,051,663 votes for and 15,262,716 votes against, and Nicholas Augustinos received 265,917,901 votes for and 47,957,634 votes against, for example.

3. 03

   Stockholders ratified the selection by the audit committee of Deloitte & Touche LLP as Dexcom's independent registered public accounting firm for the fiscal year ending December 31, 2026, the company said. The vote was 336,046,596 for, 373,544 against and 105,212 abstentions.

4. 04

   Stockholders approved, on a non-binding advisory basis, the compensation of Dexcom's named executive officers, the company said. The vote was 277,111,475 for, 36,664,959 against, 640,924 abstentions and 22,107,994 broker non-votes.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.